Is pitobrutinib available in China? What is the release date and related approval information for this drug?

Currently, Pirtobrutinib (Pirtobrutinib) has not yet been launched in the Chinese market, so domestic patients are temporarily unable to purchase the drug through formal channels. Pitobrutinib is an inhibitor that targets Bruton's tyrosine kinase (BTK) and is mainly used to treat certain types of hematological malignancies, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Although the drug has been approved and put into use in some overseas markets, its launch time in China has not yet been determined, and domestic patients need to wait for the relevant approval process to be completed before it can be used.

Pittobrutinib was developed by Genentech (Genentech) and has been approved in multiple international markets. In the United States, pitobrutinib was approved by the FDA in 2021 for the treatment of patients with chronic lymphocytic leukemia (CLL) who have developed resistance to other BTK inhibitors, such as ibrutinib. This drug is regarded as an important follow-up treatment drug, especially for those patients who develop BTK mutations during treatment. Pitobrutinib provides a new treatment option. In addition, the drug is undergoing clinical trials and approvals in many countries and regions, and is expected to be used in more markets in the future.

Although pitobrutinib has not yet been launched in China, the price of the drug is relatively high in overseas markets, especially the United States. Taking the U.S. market as an example, the price of the original version of Pitobrutinib 50mg 30 tablets is as high as approximately 100,000 RMB, which puts patients under greater financial pressure when purchasing. At the same time, generic versions of pitobrutinib have also been launched in some countries (such as Laos), and the price is relatively affordable. 50mg30 tablets only cost 2,000 RMB, which is much cheaper than the original drug. Because the production processes and quality control standards of generic drugs are different, patients should carefully evaluate the quality and reliability of the drug when choosing.

For domestic patients, the purchase of pitobrutinib is still limited. Since the drug is not currently on the market in China, patients cannot purchase it through normal domestic pharmacies or hospital channels. If patients are in urgent need of the drug, some may try to obtain it through overseas purchasing channels. However, this is also accompanied by higher risks and complicated legal procedures. In addition, with the widespread use of pitobrutinib in the international market, it is expected that the drug's marketing approval process may be accelerated, and it may be launched in the Chinese market in the future, and will be provided to patients through formal channels.

Reference materials:https://www.jaypirca.com/